The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Zynrelef
BUPIVACAINE and MELOXICAM · BUPIVACAINE 400 mg/14mL; MELOXICAM 12 mg/14mL · Solution · Infiltration · Heron Therapeutics, Inc.
NDC 47426-0501-02 · 1 CARTON in 1 KIT / 1 VIAL, SINGLE-DOSE in 1 CARTON / 14 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$325.34
Reported to Texas DSHS · 2026 annual filing · Heron Therapeutics, Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$46,533
178 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- api manufacture
- Cambrex Karlskoga ABSwedenapi manufacture
- Lifecore Biomedical, LLCUnited Statesmanufacture
- Pharma Packaging Solutions, LLCUnited Stateslabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA211988
- TE code
- —
- Approval date
- May 12, 2021
- Patents / exclusivity
- 64 patents, 4 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | I-933 | Jan 23, 2027 |
| exclusivity | I-933 | Jan 23, 2027 |
| exclusivity | I-933 | Jan 23, 2027 |
| exclusivity | I-933 | Jan 23, 2027 |
| patent | 11844837 | Apr 21, 2036 |
| patent | 11844837 | Apr 21, 2036 |
| patent | 11844837 | Apr 21, 2036 |
| patent | 11844837 | Apr 21, 2036 |
| patent | 9694079 | Apr 20, 2035 |
| patent | 9801945 | Apr 20, 2035 |
| patent | 9801945 | Apr 20, 2035 |
| patent | 9694079 | Apr 20, 2035 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · TerminatedAug 2, 2022HERON THERAPEUTICS, INC. — Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit
Manufacturers of BUPIVACAINE and MELOXICAM (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Heron Therapeutics, Inc. | BUPIVACAINE 200 mg/7mL; MELOXICAM 6 mg/7mL | Jul 15, 2026 | Sep 2, 2026 |
| Heron Therapeutics, Inc. | BUPIVACAINE 400 mg/14mL; MELOXICAM 12 mg/14mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Zynrelef — NDC 47426-0501-02," retrieved September 3, 2026, https://drugdashboards.com/drug/47426050102.
Free to cite with attribution — see how the data is put together.